International Session（Panel Discussion）1(JSH・JSGE・JSGCS)
Fri. November 6th   9:40 - 12:00   Room 8: Portopia Hotel Main Building Kairaku 1+2
IS-PD1-3_H
 Long-term outcome of nucleos(t)ide analogue treatment of chronic hepatitis B patients and efficacy of Peg-IFN add-on therapy
Fumitaka Suzuki1, Tetsuya Hosaka1, Hiromitsu Kumada1
1Department of Hepatology, Toranomon Hospital
Background & Aims: We determined the antiviral potency of nucleos(t)ide analogue(NA) treatment (entevcavir, TDF, TAF) in patients with chronic hepatitis B(CHB) infection.
Methods: The clinical data of 1340 NA-naïve patients who were on entecavir(n=1094), TDF(n=131) or TAF(n=115) treatments and 753 patients who received Tenofovir(TDF or TAF) and entevcavir or lamivudine combination therapy for emerging resistant virus was analyzed. Moreover, the efficacy of Peg-IFN add-on therapy was analyzed.
Results: Incremental increases were noted in the rates of undetectable HBV-DNA and HBsAg seroclearance, reaching 96% and 3.7%, respectively, by the tenth year of entevcavir treatment. These rates were 82% and 0% respectively, at first year of TAF. Those rates were 91% and 1% respectively, by the second year of TDF. HBsAg seroclearance rate of Tenofovir combination therapy was 2.9%(median treatment period 14 years). Seventeen NA-naïve patients experienced viral breakthrough(VB) during entevcavir or TDF treatment. Two patients experienced VB during TDF combination therapy. The patient who experienced VB had six mutations in RT region.
Ten patients received Peg-IFN add-on therapy during NA treatment. Four patients achieved HBsAg seroclearance during and after Peg-IFN add-on therapy. HBsAg levels of these 4 patients at baseline were <1,500 IU/mL.
Conclusions: Long-term NA treatment was associated with an excellent viral response. However, HBsAg seroclearance rates were low. Peg-IFN add-on therapy may be one of the effective treatments which can induce HBsAg seroclearance.
Index Term 1: nucleos(t)ide analogue
Index Term 2: peginterferon
Page Top